Monopar Therapeutics (MNPR) Exchange Rate Effect (2018 - 2025)
Monopar Therapeutics' (MNPR) quarterly Exchange Rate Effect came in at $99495.0 in Q4 2025, up 2716.22% year-on-year from $3532.9 in Q4 2024, and up 26361.44% quarter-over-quarter from $376.0 in Q3 2025.
Monopar Therapeutics (MNPR) Exchange Rate Effect (2018 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Exchange Rate Effect across 8 years of filings, most recently posting $99495.0 for Q4 2025.
- Exchange Rate Effect for Q4 2025 came in at $99495.0, up 2716.22% year-over-year; the trailing twelve-month figure through Dec 2025 was $97266.0 (up 19589.47% YoY), and the FY2025 annual result was $97266.0, up 19589.47% from the prior year.
- Exchange Rate Effect came in at $99495.0 for Q4 2025 at Monopar Therapeutics, up from $376.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $99495.0 in Q4 2025 to a low of -$48687.0 in Q4 2022.
- The 5-year median for Exchange Rate Effect is -$23.0 (2021), against an average of $4105.5.
- Peak annual rise in Exchange Rate Effect reached 313750.0% in 2022, while the deepest fall reached 2556.46% in 2022.
- Monopar Therapeutics' Exchange Rate Effect stood at $1982.0 in 2021, then slumped by 2556.46% to -$48687.0 in 2022, then soared by 82.84% to -$8357.0 in 2023, then jumped by 54.49% to -$3803.0 in 2024, then jumped by 2716.22% to $99495.0 in 2025.
- The last three Exchange Rate Effect figures came in at $99495.0 (Q4 2025), $376.0 (Q3 2025), and -$2551.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.60 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -2.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -40.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 8.68 Mn |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | 99,495.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 99,495.00 |
| Dec 31, 2025 | 99,495.00 |
| Sep 30, 2025 | 376.00 |
| Sep 30, 2025 | 376.00 |
| Jun 30, 2025 | -2,551.00 |
| Jun 30, 2025 | -2,551.00 |
| Mar 31, 2025 | -54.00 |
| Mar 31, 2025 | -54.00 |
| Dec 31, 2024 | -3,803.00 |
| Dec 31, 2024 | -3,803.00 |
| Sep 30, 2024 | 4,457.00 |
| Sep 30, 2024 | 4,457.00 |
| Jun 30, 2024 | 1,492.00 |
| Jun 30, 2024 | 1,492.00 |
| Mar 31, 2024 | -1,652.00 |
| Mar 31, 2024 | -1,652.00 |
| Dec 31, 2023 | -8,357.00 |
| Dec 31, 2023 | -8,357.00 |
| Sep 30, 2023 | 6,758.00 |
| Sep 30, 2023 | 6,758.00 |